Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review.
Ana Julia de Lima Bomfim, Stefany Mirrelle Fávero Zuze, Daiene de Morais Fabrício, Rebeca Mendes de Paula Pessoa, José Alexandre S. Crippa, Marcos Hortes N Chagas
Cannabis and Cannabinoid Research December 2023 DOI: 10.1089/can.2023.0086 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Population | Humans and animals across 36 preclinical and 23 clinical trials |
| Intervention | Cannabidiol (CBD) |
| Topics | CBD |
| Keywords | Cognition Cognitive domain Processing cognitive |
| Key findings | The authors conclude that acute and chronic CBD administration does not appear to impair cognition in humans without neuropsychiatric disorders, and preclinical studies report promising effects on animal cognitive processing. One study suggested repeated CBD dosing may improve cognition in heavy cannabis users but not in people with neuropsychiatric disorders; in animal models of such disorders, CBD appeared to reverse harm from experimental paradigms, bringing performance close to control levels. |
Abstract
Introduction: The effects of cannabidiol (CBD) on cognition has been investigated in recent years to determine the therapeutic potential of this cannabinoid for a broad gamut of medical conditions, including neuropsychiatric disorders. The aim of the present study was to perform a systematic review of studies that analyzed the effects of the acute and chronic administration of CBD on cognition in humans and animals both to assess the cognitive safety of CBD and to determine a beneficial potential of CBD on cognition.
Methods: The PubMed, Web of Science, PsycINFO, and Scopus databases were searched in December of 2022 for relevant articles using the following combinations of keywords: ("cannabidiol" OR "CBD") AND ("cognition" OR "processing cognitive" OR "memory" OR "language" OR "attention" OR "executive function" OR "social cognition" OR "perceptual motor ability" OR "processing speed").
Results: Fifty-nine articles were included in the present review (36 preclinical and 23 clinical trials). CBD seems not to have any negative effect on cognitive processing in rats. The clinical trials confirmed these findings in humans. One study found that repeated dosing with CBD may improve cognitive in people who use cannabis heavily but not individuals with neuropsychiatric disorders. Considering the context of neuropsychiatric disorders in animal models, CBD seems to reverse the harm caused by the experimental paradigms, such that the performance of these animals becomes similar to that of control animals.
Conclusions: The results demonstrate that the chronic and acute administration of CBD seems not to impair cognition in humans without neuropsychiatric disorders. In addition, preclinical studies report promising results regarding the effects of CBD on the cognitive processing of animals. Future double-blind, placebo-controlled, randomized clinical trials with larger, less selective samples, with standardized tests, and using different doses of CBD in outpatients are of particular interest to elucidate the cognitive effects of CBD.
Comparable studies
Other systematic reviews and meta-analyses on CBD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies | 2009 | Systematic review | |
| Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties | 2020 | Systematic review | |
| Effects of Cannabis on Impulsivity: A Systematic Review of Neuroimaging Findings | 2014 | Systematic review | |
| Association between formal thought disorder and cannabis use: a systematic review and meta-analysis Individuals along the psychosis continuum (healthy individuals, patients with... | 2022 | Meta-analysis | n = 5,191 |
| The Relationship Between Cannabis Use and Schizophrenia As a Risk Factor or For Its Therapeutic Potential: A Systematic Review of Evidence | 2025 | Systematic review |
Citations in the library
Cited by 2
- Impaired mnemonic pattern separation associated with PTSD symptoms paradoxically improves with regular cannabis use npj Mental Health Research April 24, 2025
- Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain. Psychopharmacology September 1, 2026
Cites 18
- Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age Frontiers in Immunology September 21, 2018
- Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life Frontiers in Pharmacology May 11, 2017
- Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol Archives of General Psychiatry April 1, 2009
- Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition Psychopharmacology May 1, 2019
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD) Brazilian Journal of Psychiatry March 1, 2010
and 13 more in the library